AbbVie Inc. (ABBV)
Here is What to Know Beyond Why AbbVie Inc. (ABBV) is a Trending Stock
AbbVie (ABBV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
3 High-Yield Dividend Growth Stocks to Buy in December and Hold for a Decade or Longer
It's been a great couple of years for the stock market. From the end of 2022 through Nov. 29, the benchmark S&P 500 (^GSPC 0.24%) index rose a whopping 57.1% higher.
3 Fantastic Dividend Stocks to Buy Sooner Rather Than Later
You don't have to be an income investor to like dividends. Many billionaires who definitely don't need income still have dividend stocks in their portfolios.
Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever
What's better than receiving passive income? Enjoying it for decades.
Why Is AbbVie (ABBV) Down 10.2% Since Last Earnings Report?
AbbVie (ABBV) reported earnings 30 days ago. What's next for the stock?
My Best Dividend Aristocrats For December 2024
The ProShares S&P 500 Dividend Aristocrat ETF is up 10.26% year-to-date through October. I present 3 strategies that can theoretically beat the dividend aristocrat index in the long term. After 40 months of tracking these strategies, two strategies are generating a CAGR superior to NOBL.
2 High-Yield Dividend Stocks to Buy Now for a Lifetime of Passive Income
Investors looking for a way to pump up their passive income streams want to turn their attention toward the pharmaceutical industry. From the end of 2022 through Nov. 22, the benchmark S&P 500 index rose by a stunning 55.5%, but many of its drug-selling components haven't participated in the rally.
Despite Neuroscience Setback, AbbVie Has Strong Recovery Ahead
AbbVie's stock dropped 17.3% due to Emraclidine's phase 2 trial failure, but management is expected to replace Humira revenues and grow the top line. Skyrizi and Rinvoq are projected to surpass Humira's peak revenues by 2027, indicating strong future growth in the immunology segment. Oncology and neuroscience segments show promise with acquisitions like ImmunoGen and Aliada, despite setbacks in schizophrenia drug development.
AbbVie Stock Rises After Leerink Partners Upgrades Its Rating
Leerink Partners upgrades its rating on ABBV stock from Market Perform to Outperform.
One Sector Has Underperformed Massively: These 4 Blue-Chip Dividend Giants Are Huge 2025 Plays
Key Points Donald Trump's victory is positive for the stock market.
Dividend Aristocrats Yielding Over 4% to Buy in November
Companies with high dividend yields are relatively uncommon in this market.
The Stock Market Is Soaring but These 2 Stocks Are Still Dirt Cheap Buys
Earlier this month, the S&P 500 hit a record high of more than 6,000 for the first time ever. Based on that, you might assume that stocks may be too expensive to buy right now as the average stock in the index is trading at more than 25 times earnings.
